Neuropeptide effects on memory in aged monkeys.
The effects of several neuropeptides were evaluated using a non-human primate model of age-related memory impairments. Several doses of ACTH4-10, lysine vasopressin, arginine vasopressin, oxytocin and somatostatin were each tested in several aged monkeys. Because data from a large number of non-drug control sessions was collected before, during and after this study, it was possible to define the normal range of control performance for each monkey and statistically determine whether a change in performance under any single dose of drug reflected a significant change from the particular monkey's normal baseline performance. Although none of the neuropeptides produced consistent group effects, evaluations of individual subjects against their own baseline performance revealed reliable changes at certain doses. Arginine vasopressin appeared to produce the best overall effects with three of the five monkeys exhibiting reliable changes in performance from baseline. These same three monkeys also responded positively to the lysine form. Oxytocin impaired memory in three of the six aged monkeys tested over a wide range of doses. Three of six aged monkeys performed better under ACTH4-10 compared to baseline; however, in two of these cases only a single dose was effective. The performance of only one subject was improved under somatostatin, and this was at a single dose only. The data reported here provide evidence for neuropeptides producing behavioral improvement in non-human primates using an appetitive task, eliminating a popular criticism that the data in this literature has depended too heavily on the testing of rodents in shock-motivated tasks. Additionally, the improvements observed in this study involve a behavior that it naturally impaired by age and one which has many operational similarities and some empirical relevance to measures of recent memory in humans. However, these positive findings must be tempered by the lack of robust effects and high individual variation observed.
D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000375:Aging; D000818:Animals; D001127:Arginine Vasopressin / Q000494:pharmacology; D002428:Cebus; D004305:Dose-Response Relationship, Drug; D005260:Female; D008236:Lypressin / Q000494:pharmacology; D008297:Male; D008568:Memory / Q000187:drug effects*; D010121:Oxytocin / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology*; D013004:Somatostatin / Q000494:pharmacology
D010446:Peptide Fragments; D010455:Peptides; D001127:Arginine Vasopressin; D010121:Oxytocin; D008236:Lypressin; D013004:Somatostatin; D000324:Adrenocorticotropic Hormone; C011394:ACTH (4-10)